Neurodegenerative Diseases Progression Markers (MARKERS-NDD)

Recruiting Observational Study
Neurodegenerative Diseases Parkinson Disease Synucleinopathies Lewy Body Disease Multiple System Atrophy Tauopathies Alzheimer Disease Corticobasal Degeneration Supranuclear Palsy, Progressive Atypical Parkinsonism TDP-43 Proteinopathies Amyotrophic Lateral Sclerosis Frontotemporal Lobar Degeneration Movement Disorders Cognitive Impairment Dementia Iron Overload Neurodegeneration With Brain Iron Accumulation (NBIA)
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
10 and older
Sex
Any
Study type
Observational
Participants needed
600 (estimated)
Sponsor
Casa di Cura San Raffaele Cassino · Research network
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
MARKERS-NDD is a prospective, observational, longitudinal study, which aims to collect data from patients affected by neurodegenerative diseases (NDD) followed longitudinally for routine examinations performed as part of normal clinical practice. Data collected from clinical evaluations, movement analysis, brain imaging, neuropsychological and electroencephalographic assessments, blood chemistry t…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Patients with diagnosis of Parkinson's Disease, Parkinsonism and Movement Disorders * Patients with diagnosis of Parkinson's Disease * Diagnosis of Parkinson's Disease according to the United Kingdom (UK) Parkinson's Disease Society Brain Bank * Diagnosis of Movement…
Contacts

Maria Francesca De Pandis, MD, PhD, Neurologist

0776394740

maria.depandis@sanraffaele.it

CONTACT

Maria Gaglione

0776394740

maria.gaglione@sanraffaele.it

CONTACT